Trial Profile
A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD5363 Under Adaptable Dosing Schedules in Patients With Advanced Solid Malignancies
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 24 Jan 2024
Price :
$35
*
At a glance
- Drugs Capivasertib (Primary) ; Fulvestrant
- Indications Advanced breast cancer; Cervical cancer; Endometrial cancer; Ovarian cancer; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors AstraZeneca
- 19 Jan 2024 Planned End Date changed from 31 Dec 2023 to 31 Dec 2024.
- 29 Mar 2023 Planned End Date changed from 29 Dec 2023 to 31 Dec 2023.
- 22 Dec 2022 Planned End Date changed from 30 Dec 2022 to 29 Dec 2023.